サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1518872

抗VEGF市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年

Anti-VEGF Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 422 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
抗VEGF市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年
出版日: 2024年07月18日
発行: Persistence Market Research
ページ情報: 英文 422 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Researchはこのほど、抗VEGF市場に関する包括的なレポートを発表しました。当レポートでは、促進要因・動向・機会・課題を含む重要な市場ダイナミクスを徹底的に評価し、市場構造に関する詳細な洞察を提供しています。

主要な洞察

  • 抗VEGF市場規模（2024年）：238億米ドル
  • 予測市場金額（2033年）：351億米ドル
  • 世界市場成長率（CAGR 2024年～2033年）：4.4%

抗VEGF市場 - 調査範囲：

抗VEGF療法は、加齢黄斑変性症（AMD）、糖尿病性網膜症、ある種のがんを含む様々な疾患の治療において重要な役割を果たしています。これらの治療薬は血管内皮増殖因子（VEGF）を標的として血管新生を阻害し、疾患の進行を効果的に管理します。抗VEGF市場は、主に病院、診療所、眼科センター、専門治療施設を対象としており、硝子体内注射や経口薬など、さまざまな治療オプションを提供しています。

市場成長の促進要因：

世界のAMDと糖尿病性網膜症の有病率の増加、薬剤の有効性と患者の予後を向上させるバイオテクノロジーの進歩、抗VEGF療法による早期介入の利点に関する医療従事者の意識の高まりなどです。ドラッグデリバリーシステムの技術革新と遠隔医療サービスの拡大は、治療へのアクセス性と患者のコンプライアンスを向上させ、市場の成長をさらに後押しします。

市場抑制要因：

有望な成長見通しにもかかわらず、抗VEGF市場は、高額な治療費、医薬品承認や市場参入に関する規制の複雑さ、長期治療に伴う潜在的な副作用に関連する課題に直面しています。また、特定の地域では抗VEGF治療に対する償還範囲が限られていることも、特にヘルスケア支出の効率的な管理に努める新興国において、市場拡大の障壁となっています。

市場機会：

抗VEGF市場は、新規製剤、個別化医療アプローチ、複数の疾患経路をターゲットとした併用療法に焦点を当てた研究開発が進行中であり、大きな成長機会をもたらしています。製薬企業、研究機関、ヘルスケアプロバイダーの戦略的提携は、技術革新を加速し、眼科および腫瘍学のアンメットメディカルニーズに対応するために不可欠です。

本レポートで扱う主要な質問

  • 抗VEGF市場の世界的成長を促進する主要な要因は何か？
  • 異なるヘルスケア環境において抗VEGFの採用を促進している治療用途と患者層は何か？
  • 技術の進歩は抗VEGF市場の競合情勢をどのように変えているか？
  • 抗VEGF市場に貢献している主要企業はどこで、市場の関連性を維持するためにどのような戦略を採用しているのか？
  • 世界の抗VEGF市場における新たな動向と将来展望は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲 /分類
  • 市場の定義 / 範囲 / 制限
  • 包含事項・除外事項

第3章 主要な市場動向

  • 市場に影響を与える主要な動向
  • 製品イノベーション / 開発動向

第4章 主要な成功要因

  • 規制状況
  • パイプライン評価
  • 製品の採用と使用状況の分析
  • 企業が採用する主要なマーケティングおよびプロモーション戦略
  • PESTLE分析
  • ポーター分析
  • バリューチェーン分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因 - 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 収益：薬剤タイプ別
    • 収益：タイプ別
    • 収益：疾患適応症別
    • 収益：流通チャネル別
    • 国別
  • 2024年の市場シナリオ

第7章 世界市場の需要（金額または規模、10億米ドル）分析

  • 過去の市場金額（10億米ドル）の分析、2019年～2023年
  • 現在および将来の市場金額（10億米ドル）予測、2024年～2033年
    • 前年比成長動向分析
    • 絶対額の機会分析

第8章 世界市場分析：薬剤タイプ別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（10億米ドル）分析：薬剤タイプ別、2019年～2023年
  • の現在および将来の市場規模（10億米ドル）の分析と予測：薬剤タイプ別、2024年～2033年
    • 小分子
    • 生物学的製剤
  • 市場の魅力分析：薬剤タイプ別

第9章 世界市場分析：タイプ別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（10億米ドル）分析：タイプ別、2019年～2023年
  • 現在および将来の市場規模（10億米ドル）分析と予測：タイプ別、2024年～2033年
    • VEGF A阻害剤
    • VEGF B阻害剤
    • VEGF C阻害剤
    • 胎盤成長因子阻害剤
  • 市場の魅力分析：タイプ別

第10章 世界市場分析：疾患適応症別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（10億米ドル）分析：疾患適応症別、2019年～2023年
  • 現在および将来の市場規模（10億米ドル）の分析と予測：疾患適応症別、2024年～2033年
    • 腫瘍学
    • 血液疾患
    • 眼科疾患
  • 市場の魅力分析：疾患適応症別

第11章 世界市場分析：流通チャネル別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（10億米ドル）分析：流通チャネル別、2019年～2023年
  • 現在および将来の市場規模（10億米ドル）の分析と予測：流通チャネル別、2024年～2033年
    • 病院
    • 専門クリニック
    • がん研究センター
    • 通信販売薬局
  • 市場の魅力分析：流通チャネル別

第12章 世界市場分析：地域別

  • イントロダクション
  • 過去の市場規模（10億米ドル）の分析：地域別、2019年～2023年
  • 現在および将来の市場規模（10億米ドル）の分析と予測：地域別、2024年～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ（MEA）
  • 市場の魅力分析：地域別

第13章 北米市場分析

第14章 ラテンアメリカ市場分析

第15章 欧州市場分析

第16章 東アジア市場分析

第17章 南アジア市場分析

第18章 オセアニア市場

第19章 中東・アフリカ（MEA）市場分析

第20章 市場構造分析

  • 市場分析：企業階層別
  • 主要企業の市場シェア分析
  • 市場集中
  • 市場プレゼンス分析

第21章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細情報
    • Pfizer Inc.
    • Bayer AG
    • Novartis AG
    • Sanofi SA
    • Exelixis Inc.
    • Eisai Co. Ltd.
    • Amgen Inc.
    • F. Hoffmann-La Roche Ltd.
    • Eli Lilly and Company
    • Amneal Pharmaceuticals Inc.
    • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
    • Takeda Pharmaceutical Co. Ltd.
    • Sino Biopharma
    • HUTCHMED

第22章 使用される前提条件と頭字語

第23章 調査手法

目次
Product Code: PMRREP33422

Persistence Market Research has recently released a comprehensive report on the Anti-VEGF Market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • Anti-VEGF Market Size (2024E): USD 23.8 Billion
  • Projected Market Value (2033F): USD 35.1 Billion
  • Global Market Growth Rate (CAGR 2024 to 2033): 4.4%

Anti-VEGF Market - Report Scope:

Anti-VEGF therapies play a critical role in the treatment of various medical conditions, including age-related macular degeneration (AMD), diabetic retinopathy, and certain types of cancers. These therapies target vascular endothelial growth factor (VEGF) to inhibit angiogenesis and manage disease progression effectively. The Anti-VEGF Market caters primarily to hospitals, clinics, ophthalmology centers, and specialized treatment facilities, offering a range of treatment options, including intravitreal injections and oral medications.

Market Growth Drivers:

The global Anti-VEGF Market is driven by several key factors, including increasing prevalence of AMD and diabetic retinopathy globally, advancements in biotechnology enhancing drug efficacy and patient outcomes, and growing awareness among healthcare providers about the benefits of early intervention with Anti-VEGF therapies. Technological innovations in drug delivery systems and the expansion of telemedicine services further bolster market growth by improving treatment accessibility and patient compliance.

Market Restraints:

Despite promising growth prospects, the Anti-VEGF Market faces challenges related to high treatment costs, regulatory complexities governing drug approvals and market entry, and potential adverse effects associated with long-term therapy. Limited reimbursement coverage for Anti-VEGF treatments in certain regions also poses barriers to market expansion, particularly in emerging economies striving to manage healthcare expenditures effectively.

Market Opportunities:

The Anti-VEGF Market presents significant growth opportunities driven by ongoing research and development initiatives focused on novel drug formulations, personalized medicine approaches, and combination therapies targeting multiple disease pathways. Strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers are essential to accelerate innovation and address unmet medical needs in ophthalmology and oncology.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Anti-VEGF Market globally?
  • Which therapeutic applications and patient populations are driving Anti-VEGF adoption across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the Anti-VEGF Market?
  • Who are the key players contributing to the Anti-VEGF Market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global Anti-VEGF Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Anti-VEGF Market, including Roche Holding AG, Novartis AG, and Regeneron Pharmaceuticals, Inc., focus on innovation, strategic alliances, and regulatory compliance to gain a competitive edge. These companies invest significantly in clinical trials, regulatory submissions, and post-marketing surveillance to ensure product safety and efficacy. Collaborations with ophthalmologists, oncologists, and patient advocacy groups facilitate market access and promote therapeutic advancements in Anti-VEGF therapy.

Key Companies Profiled:

  • Pfizer Inc.
  • Novartis AG
  • Sanofi SA
  • Bayer Healthcare LLC
  • F. Hoffmann-La Roche Ltd.
  • Amgen Inc.
  • Eli Lilly and Company
  • Eisai Co., Ltd.
  • Sino Pharma
  • Amneal Pharmaceuticals Inc.
  • Exelixis, Inc.
  • HUTCHMED

Key Segments of Anti-VEGF Industry Research

By Drug:

  • Small Molecules
  • Biologics

By Type:

  • VEGF-A Inhibitors
  • VEGF-B Inhibitors
  • VEGF-C Inhibitors
  • Placenta Growth Factor Inhibitors

By Disease Indication:

  • Oncology
  • Hematology Disorders
  • Ophthalmology Disorders

By Distribution Channel:

  • Hospitals
  • Specialty Clinics
  • Mail Order Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage/Taxonomy
  • 2.2. Market Definition/Scope/Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Regulatory Landscape
  • 4.2. Pipeline Assessment
  • 4.3. Product Adoption and Usage Analysis
  • 4.4. Key Marketing & Promotional Strategies Adopted by Companies
  • 4.5. PESTLE Analysis
  • 4.6. Porters Analysis
  • 4.7. Value Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Spending Outlook
    • 5.1.3. Global Oncology Therapeutic Medicines Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Increase in R&D Funding and Grants
    • 5.2.2. Rising Research Activities for Rare Disease Indications
    • 5.2.3. High Demand for Biologics
    • 5.2.4. Surge in Research Collaborations for Development of Drugs
    • 5.2.5. High Prevalence of Cancer
    • 5.2.6. New Product Launch
    • 5.2.7. Regulatory Approvals
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. Revenue By Drug Types
    • 6.1.2. Revenue By Types
    • 6.1.3. Revenue By Disease Indication
    • 6.1.4. Revenue By Distribution Channel
    • 6.1.5. Revenue By Country
  • 6.2. 2024 Market Scenario

7. Global Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Types

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Drug Types, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug Types, 2024-2033
    • 8.3.1. Small Molecules
      • 8.3.1.1. Pazopanib
      • 8.3.1.2. Sunitinib
      • 8.3.1.3. Regorafenib
      • 8.3.1.4. Cabozantinib
      • 8.3.1.5. Lenvatinib
      • 8.3.1.6. Ponatinib
      • 8.3.1.7. Cabozantinib
      • 8.3.1.8. Axitinib
      • 8.3.1.9. Tivozanib
      • 8.3.1.10. Vandetanib
      • 8.3.1.11. Sorafenib
      • 8.3.1.12. Anlotinib
      • 8.3.1.13. Apatinib
      • 8.3.1.14. Fruquintinib
      • 8.3.1.15. Surufatinib
    • 8.3.2. Biologics
      • 8.3.2.1. Bevacizumab
      • 8.3.2.2. Ziv-Aflibercept
      • 8.3.2.3. Ramucirumab
      • 8.3.2.4. Ranibizumab
  • 8.4. Market Attractiveness Analysis By Drug Types

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Types

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Types, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Types, 2024-2033
    • 9.3.1. VEGF A Inhibitors
    • 9.3.2. VEGF B Inhibitors
    • 9.3.3. VEGF C Inhibitors
    • 9.3.4. Placenta Growth Factor Inhibitors
  • 9.4. Market Attractiveness Analysis By Types

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Disease Indication

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Disease Indication, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Disease Indication, 2024-2033
    • 10.3.1. Oncology
      • 10.3.1.1. Cervical Cancer
      • 10.3.1.2. Non-Small Cell Lung Cancer
      • 10.3.1.3. Renal Cell Carcinoma
      • 10.3.1.4. Soft Tissue Sarcoma
      • 10.3.1.5. Colorectal Cancer
      • 10.3.1.6. Liver Cancer
      • 10.3.1.7. Others
    • 10.3.2. Hematology Disorders
    • 10.3.3. Ophthalmology Disorders
      • 10.3.3.1. Wet Age-Related Macular Degeneration (AMD)
      • 10.3.3.2. Diabetic Retinopathy
      • 10.3.3.3. Others
  • 10.4. Market Attractiveness Analysis By Disease Indication

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
  • 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
    • 11.3.1. Hospitals
    • 11.3.2. Specialty Clinics
    • 11.3.3. Cancer Research Centers
    • 11.3.4. Mail Order Pharmacies
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
  • 12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2033
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Drug Types
    • 13.3.3. By Types
    • 13.3.4. By Disease Indication
    • 13.3.5. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Drug Types
    • 13.4.3. By Types
    • 13.4.4. By Disease Indication
    • 13.4.5. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. U.S. Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Drug Types
        • 13.8.1.2.2. By Types
        • 13.8.1.2.3. By Disease Indication
        • 13.8.1.2.4. By Distribution Channel
    • 13.8.2. Canada Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Drug Types
        • 13.8.2.2.2. By Types
        • 13.8.2.2.3. By Disease Indication
        • 13.8.2.2.4. By Distribution Channel

14. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. Mexico
      • 14.3.1.2. Brazil
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Drug Types
    • 14.3.3. By Types
    • 14.3.4. By Disease Indication
    • 14.3.5. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Drug Types
    • 14.4.3. By Types
    • 14.4.4. By Disease Indication
    • 14.4.5. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Mexico Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Drug Types
        • 14.8.1.2.2. By Types
        • 14.8.1.2.3. By Disease Indication
        • 14.8.1.2.4. By Distribution Channel
    • 14.8.2. Brazil Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Drug Types
        • 14.8.2.2.2. By Types
        • 14.8.2.2.3. By Disease Indication
        • 14.8.2.2.4. By Distribution Channel
    • 14.8.3. Argentina Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Drug Types
        • 14.8.3.2.2. By Types
        • 14.8.3.2.3. By Disease Indication
        • 14.8.3.2.4. By Distribution Channel

15. Europe Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. BENELUX
      • 15.3.1.7. Nordic Countries
      • 15.3.1.8. Russia
      • 15.3.1.9. Rest of Europe
    • 15.3.2. By Drug Types
    • 15.3.3. By Types
    • 15.3.4. By Disease Indication
    • 15.3.5. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Drug Types
    • 15.4.3. By Types
    • 15.4.4. By Disease Indication
    • 15.4.5. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Drug Types
        • 15.8.1.2.2. By Types
        • 15.8.1.2.3. By Disease Indication
        • 15.8.1.2.4. By Distribution Channel
    • 15.8.2. Italy Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Drug Types
        • 15.8.2.2.2. By Types
        • 15.8.2.2.3. By Disease Indication
        • 15.8.2.2.4. By Distribution Channel
    • 15.8.3. France Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Drug Types
        • 15.8.3.2.2. By Types
        • 15.8.3.2.3. By Disease Indication
        • 15.8.3.2.4. By Distribution Channel
    • 15.8.4. U.K. Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Drug Types
        • 15.8.4.2.2. By Types
        • 15.8.4.2.3. By Disease Indication
        • 15.8.4.2.4. By Distribution Channel
    • 15.8.5. Spain Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Drug Types
        • 15.8.5.2.2. By Types
        • 15.8.5.2.3. By Disease Indication
        • 15.8.5.2.4. By Distribution Channel
    • 15.8.6. BENELUX Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Drug Types
        • 15.8.6.2.2. By Types
        • 15.8.6.2.3. By Disease Indication
        • 15.8.6.2.4. By Distribution Channel
    • 15.8.7. Nordic Countries Market Analysis
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Drug Types
        • 15.8.7.2.2. By Types
        • 15.8.7.2.3. By Disease Indication
        • 15.8.7.2.4. By Distribution Channel
    • 15.8.8. Russia Market Analysis
      • 15.8.8.1. Introduction
      • 15.8.8.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.8.2.1. By Drug Types
        • 15.8.8.2.2. By Types
        • 15.8.8.2.3. By Disease Indication
        • 15.8.8.2.4. By Distribution Channel

16. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Drug Types
    • 16.3.3. By Types
    • 16.3.4. By Disease Indication
    • 16.3.5. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Drug Types
    • 16.4.3. By Types
    • 16.4.4. By Disease Indication
    • 16.4.5. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. China Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Drug Types
        • 16.8.1.2.2. By Types
        • 16.8.1.2.3. By Disease Indication
        • 16.8.1.2.4. By Distribution Channel
    • 16.8.2. Japan Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Drug Types
        • 16.8.2.2.2. By Types
        • 16.8.2.2.3. By Disease Indication
        • 16.8.2.2.4. By Distribution Channel
    • 16.8.3. South Korea Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Drug Types
        • 16.8.3.2.2. By Types
        • 16.8.3.2.3. By Disease Indication
        • 16.8.3.2.4. By Distribution Channel

17. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. India
      • 17.3.1.2. Indonesia
      • 17.3.1.3. Malaysia
      • 17.3.1.4. Thailand
      • 17.3.1.5. Rest of South Asia
    • 17.3.2. By Drug Types
    • 17.3.3. By Types
    • 17.3.4. By Disease Indication
    • 17.3.5. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Drug Types
    • 17.4.3. By Types
    • 17.4.4. By Disease Indication
    • 17.4.5. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. India Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Drug Types
        • 17.8.1.2.2. By Types
        • 17.8.1.2.3. By Disease Indication
        • 17.8.1.2.4. By Distribution Channel
    • 17.8.2. Indonesia Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Drug Types
        • 17.8.2.2.2. By Types
        • 17.8.2.2.3. By Disease Indication
        • 17.8.2.2.4. By Distribution Channel
    • 17.8.3. Malaysia Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Drug Types
        • 17.8.3.2.2. By Types
        • 17.8.3.2.3. By Disease Indication
        • 17.8.3.2.4. By Distribution Channel
    • 17.8.4. Thailand Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Drug Types
        • 17.8.4.2.2. By Types
        • 17.8.4.2.3. By Disease Indication
        • 17.8.4.2.4. By Distribution Channel

18. Oceania Market 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Drug Types
    • 18.3.3. By Types
    • 18.3.4. By Disease Indication
    • 18.3.5. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Drug Types
    • 18.4.3. By Types
    • 18.4.4. By Disease Indication
    • 18.4.5. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Drug Types
        • 18.8.1.2.2. By Types
        • 18.8.1.2.3. By Disease Indication
        • 18.8.1.2.4. By Distribution Channel
    • 18.8.2. New Zealand Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Drug Types
        • 18.8.2.2.2. By Types
        • 18.8.2.2.3. By Disease Indication
        • 18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkey
      • 19.3.1.3. South Africa
      • 19.3.1.4. North Africa
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By Drug Types
    • 19.3.3. By Types
    • 19.3.4. By Disease Indication
    • 19.3.5. By Distribution Channel
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Drug Types
    • 19.4.3. By Types
    • 19.4.4. By Disease Indication
    • 19.4.5. By Distribution Channel
  • 19.5. Market Trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Drug Types
        • 19.8.1.2.2. By Types
        • 19.8.1.2.3. By Disease Indication
        • 19.8.1.2.4. By Distribution Channel
    • 19.8.2. Turkey Anti-VEGF Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Drug Types
        • 19.8.2.2.2. By Types
        • 19.8.2.2.3. By Disease Indication
        • 19.8.2.2.4. By Distribution Channel
    • 19.8.3. South Africa Market Analysis
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Drug Types
        • 19.8.3.2.2. By Types
        • 19.8.3.2.3. By Disease Indication
        • 19.8.3.2.4. By Distribution Channel
    • 19.8.4. North Africa Market Analysis
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Drug Types
        • 19.8.4.2.2. By Types
        • 19.8.4.2.3. By Disease Indication
        • 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Concentration
  • 20.4. Market Presence Analysis
    • 20.4.1. Regional Footprint Analysis
    • 20.4.2. Channel Footprint Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. Pfizer Inc.
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Sales Footprint
      • 21.3.1.4. Key Financial
      • 21.3.1.5. Key Developments
      • 21.3.1.6. SWOT Analysis
      • 21.3.1.7. Strategy Overview
        • 21.3.1.7.1. Marketing Strategies
        • 21.3.1.7.2. Channel Strategies
    • 21.3.2. Bayer AG
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Sales Footprint
      • 21.3.2.4. Key Financial
      • 21.3.2.5. Key Developments
      • 21.3.2.6. SWOT Analysis
      • 21.3.2.7. Strategy Overview
        • 21.3.2.7.1. Marketing Strategies
        • 21.3.2.7.2. Channel Strategies
    • 21.3.3. Novartis AG
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Sales Footprint
      • 21.3.3.4. Key Financial
      • 21.3.3.5. Key Developments
      • 21.3.3.6. SWOT Analysis
      • 21.3.3.7. Strategy Overview
        • 21.3.3.7.1. Marketing Strategies
        • 21.3.3.7.2. Channel Strategies
    • 21.3.4. Sanofi SA
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Sales Footprint
      • 21.3.4.4. Key Financial
      • 21.3.4.5. Key Developments
      • 21.3.4.6. SWOT Analysis
      • 21.3.4.7. Strategy Overview
        • 21.3.4.7.1. Marketing Strategies
        • 21.3.4.7.2. Channel Strategies
    • 21.3.5. Exelixis Inc.
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Sales Footprint
      • 21.3.5.4. Key Financial
      • 21.3.5.5. Key Developments
      • 21.3.5.6. SWOT Analysis
      • 21.3.5.7. Strategy Overview
        • 21.3.5.7.1. Marketing Strategies
        • 21.3.5.7.2. Channel Strategies
    • 21.3.6. Eisai Co. Ltd.
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Sales Footprint
      • 21.3.6.4. Key Financial
      • 21.3.6.5. Key Developments
      • 21.3.6.6. SWOT Analysis
      • 21.3.6.7. Strategy Overview
        • 21.3.6.7.1. Marketing Strategies
        • 21.3.6.7.2. Channel Strategies
    • 21.3.7. Amgen Inc.
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Sales Footprint
      • 21.3.7.4. Key Financial
      • 21.3.7.5. Key Developments
      • 21.3.7.6. SWOT Analysis
      • 21.3.7.7. Strategy Overview
        • 21.3.7.7.1. Marketing Strategies
        • 21.3.7.7.2. Channel Strategies
    • 21.3.8. F. Hoffmann-La Roche Ltd.
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Sales Footprint
      • 21.3.8.4. Key Financial
      • 21.3.8.5. Key Developments
      • 21.3.8.6. SWOT Analysis
      • 21.3.8.7. Strategy Overview
        • 21.3.8.7.1. Marketing Strategies
        • 21.3.8.7.2. Channel Strategies
    • 21.3.9. Eli Lilly and Company
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Sales Footprint
      • 21.3.9.4. Key Financial
      • 21.3.9.5. Key Developments
      • 21.3.9.6. SWOT Analysis
      • 21.3.9.7. Strategy Overview
        • 21.3.9.7.1. Marketing Strategies
        • 21.3.9.7.2. Channel Strategies
    • 21.3.10. Amneal Pharmaceuticals Inc.
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Sales Footprint
      • 21.3.10.4. Key Financial
      • 21.3.10.5. Key Developments
      • 21.3.10.6. SWOT Analysis
      • 21.3.10.7. Strategy Overview
        • 21.3.10.7.1. Marketing Strategies
        • 21.3.10.7.2. Channel Strategies
    • 21.3.11. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
      • 21.3.11.1. Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Sales Footprint
      • 21.3.11.4. Key Financial
      • 21.3.11.5. Key Developments
      • 21.3.11.6. SWOT Analysis
      • 21.3.11.7. Strategy Overview
        • 21.3.11.7.1. Marketing Strategies
        • 21.3.11.7.2. Channel Strategies
    • 21.3.12. Takeda Pharmaceutical Co. Ltd.
      • 21.3.12.1. Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Sales Footprint
      • 21.3.12.4. Key Financial
      • 21.3.12.5. Key Developments
      • 21.3.12.6. SWOT Analysis
      • 21.3.12.7. Strategy Overview
        • 21.3.12.7.1. Marketing Strategies
        • 21.3.12.7.2. Channel Strategies
    • 21.3.13. Sino Biopharma
      • 21.3.13.1. Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Sales Footprint
      • 21.3.13.4. Key Financial
      • 21.3.13.5. Key Developments
      • 21.3.13.6. SWOT Analysis
      • 21.3.13.7. Strategy Overview
        • 21.3.13.7.1. Marketing Strategies
        • 21.3.13.7.2. Channel Strategies
    • 21.3.14. HUTCHMED
      • 21.3.14.1. Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Sales Footprint
      • 21.3.14.4. Key Financial
      • 21.3.14.5. Key Developments
      • 21.3.14.6. SWOT Analysis
      • 21.3.14.7. Strategy Overview
        • 21.3.14.7.1. Marketing Strategies
        • 21.3.14.7.2. Channel Strategies

22. Assumptions and Acronyms Used

23. Research Methodology